Article
Dallas - An analysis of more than 100 patients shows that darker-skinned patients benefit from light therapy to treat morphea and related diseases as much as lighter-skinned patients, according to ScienceDaily.
Dallas
- An analysis of more than 100 patients shows that darker-skinned patients benefit from light therapy to treat morphea and related diseases as much as lighter-skinned patients, according to ScienceDaily.
Researchers say the new data indicate that skin type does not significantly influence the effectiveness of UVA1 phototherapy. Researchers reviewed 101 cases treated at UT Southwestern's phototherapy clinic over three years, noting demographic and diagnostic data, skin type and clinical outcome, using standard improvement scales. They noted cumulative dose used did not vary significantly between skin types.
Most patients treated were diagnosed with either morphea or scleroderma.